Thomas Raquela J, Bartee Mee Y, Valenzuela-Cardenas Miriam, Bartee Eric
Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
Mol Ther Oncolytics. 2023 Sep 1;30:316-319. doi: 10.1016/j.omto.2023.08.014. eCollection 2023 Sep 21.
Oncolytic viruses are being heavily investigated as novel methods to treat cancers; however, predicting their therapeutic efficacy remains challenging. The most commonly used predictive tests involve determining the susceptibility of a tumor's malignant cells to infection with an oncolytic agent. Whether these tests are truly predictive of efficacy, however, remains unclear. Here we demonstrate that a recombinant, oncolytic myxoma virus shows efficacy in two murine models of triple negative breast cancer despite extremely low permissivity of these models to viral infection. These data demonstrate that infectivity studies are not an accurate surrogate for therapeutic efficacy and suggest that other tests need to be developed.
溶瘤病毒作为治疗癌症的新方法正在受到广泛研究；然而，预测其治疗效果仍然具有挑战性。最常用的预测性测试包括确定肿瘤恶性细胞对溶瘤剂感染的敏感性。然而，这些测试是否真的能预测疗效仍不清楚。在这里，我们证明了一种重组溶瘤黏液瘤病毒在两种三阴性乳腺癌小鼠模型中显示出疗效，尽管这些模型对病毒感染的允许性极低。这些数据表明，感染性研究并非治疗效果的准确替代指标，并表明需要开发其他测试。
